GlassScriptPhysician profile
Gerald G Osborn
NPI 1023093937
$1,192.78
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.50 · 2020: $29.77 · 2021: $147 · 2022: $86.44 · 2023: $404 · 2024: $279 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835 · Education: $78.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.36 |
| Education | $78.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $359.92 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $173.84 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.17 | 2021-2025 | Caplyta |
| Abbvie INC. | $117.56 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.42 | 2022-2025 | |
| Corcept Therapeutics | $59.88 | 2024 | Korlym |
| Philips North America LLC | $49.68 | 2020-2024 | (Ck7) Extended Holter |
| Novo Nordisk INC | $39.50 | 2022-2023 | Rybelsus, Ozempic |
| Cequr Corporation | $37.32 | 2024 | Cequr Simplicity |
| Intra-Sana Laboratories | $30.97 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Corium, LLC | $25.98 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $19.86 | 2022 | |
| Glaxosmithkline, LLC. | $19.18 | 2024 | Trelegy Ellipta |
| Alkermes, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.